

# Supplemental Material

## Table of Contents:

### Supplemental Tables:

**Supplemental Table 1:** Characteristics of the Healthy Controls

**Supplemental Table 2:** Summary of binding and neutralizing antibody profiles of healthy controls prior to, and at 1 Month following third mRNA SARS-CoV-2 vaccine dose.

**Supplemental Table 3:** Receiver operating characteristic curve and optimal cut-off analysis

**Supplemental Table 4:** Conversion of relative ratios to international units (BAU/mL) for plasma or serum.

### Supplemental Figures:

**Supplemental Figure 1:** Nucleocapsid Ab profile, and correlation between anti-spike and anti-RBD at Month 1

**Supplemental Figure 2:** Anti-RBD and Anti-spike antibody levels 1 month after mRNA-1273 (Moderna), BNT162b2 (Pfizer- BioNTech), or mixed vaccination.

**Supplemental Figure 3:** Relationship between Month 1 binding antibody response and antibody decline at Month 3

**Supplemental Figure 4:** Correlation between anti-spike and anti-RBD and Nucleocapsid Ab profile at Month 3

**Supplemental Figure 5:** Detection of neutralization antibodies against SARS-CoV-2 wild-type, Beta, Delta and Omicron (BA.1) variants 1 month after mRNA-1273 (Moderna), BNT162b2 (Pfizer-BioNTech), or mixed vaccination.

**Supplemental Figure 6:** Fold-reduction in neutralizing antibodies for all variants compare to wild-type.

**Supplemental Figure 7:** Comparison of binding antibody levels detected in healthy controls and kidney transplant recipients pre and post-third vaccine dose.

**Supplemental Figure 8:** Fold-reduction in neutralizing antibodies for all variants compared to wild-type in healthy controls.

**Supplemental Figure 9:** Differences in anti-RBD and anti-spike antibody levels between responders and non- responders.

**Supplemental Figure 10:** Correlations between anti-spike/RBD IgG responses and neutralizing antibodies.

**Supplemental Table 1: Characteristics of the Healthy Controls (n=13)**

Male sex	n (%)	4 (30.7)
Age (years)	Median [IQR]	46 [31-55]
Initial (2-dose) Vaccine Series n (%)		
	Pfizer-BioNTech (BNT162b2)	13 (100)
Dose 3 Vaccine n (%)		
	Pfizer-BioNTech (BNT162b2)	13 (100)

Abbreviations: IQR: Inter-quartile range.

**Supplemental Table 2. Summary of binding and neutralizing antibody profiles of healthy controls prior to, and at 1 Month following third mRNA SARS-CoV-2 vaccine dose.**

Binding Antibody	Relative ratio (median [IQR])		No. (%) participants with seropositivity		No. (%) participants with antibody levels $\geq$ median convalescent level	
	Pre-third dose N=13	1 month post 3 <sup>rd</sup> dose N=13	Pre-third dose N=13	1 month post 3 <sup>rd</sup> dose N=13	Pre-third dose N=13	1 month post 3 <sup>rd</sup> dose N=13
Anti-spike	1.285 [0.860 – 1.378]	1.825 [1.824 – 1.890]	13 (100)	13 (100)	3 (23.1)	13 (100)
Anti-RBD	0.669 [0.387 – 0.858]	1.813 [1.892 – 1.94]	12 (92.3)	13 (100)	1 (7.1)	13 (100)
Anti-nucleocapsid	0.05 [0.036 – 0.070]	0.061 [0.055 – 0.078]	0 (0)	0 (0)	0 (0)	0 (0)
Neutralizing antibody						
Neutralizing antibody	Log <sub>10</sub> ID <sub>50</sub> (median [IQR]) (of responding patients)		No. (%) participants with detectable neutralizing antibody			
	Pre-third dose N=13	1 month post 3 <sup>rd</sup> dose N=13	Pre-third dose N=13	1 month post 3 <sup>rd</sup> dose N=13		
Wild Type	2.163 [1.750 – 2.261]	3.782 [3.614 – 3.998]	13 (100)	13 (100)		
Beta	1.737 [1.131 – 2.075]	3.399 [3.318 – 3.641]	12 (92.3)	13 (100)		
Delta	1.887 [1.646 – 2.150]	3.602 [3.282 – 3.720]	12 (92.3)	13 (100)		
Omicron	1.563 [1.646 – 2.150]	2.595 [2.538 – 2.646]	5 (38.5)	13 (100)		

**Supplemental Table 3: Receiver operating characteristic curve and optimal cut-off analysis**

Variant	Antibody	AUC	95% CI	Threshold	Specificity	Sensitivity	TN	TP	FN	FP
Wild Type	Anti-RBD	0.99	96.74-100%	0.317	100	98.88	12	31	1	0
	Anti-SmT1	0.965	89.56-100%	1.319	91.66	87.5	11	28	4	1
Beta (B.1.351)	Anti-RBD	0.998	99.21-100%	0.932	100	96	19	24	1	0
	Anti-SmT1	0.987	96.56-100%	1.481	94.74	96	18	24	1	1
Delta (B.1.617.2)	Anti-RBD	1	NA	0.627	100	100	16	28	0	0
	Anti-SmT1	0.978	94.39-100%	1.391	93.75	89.29	15	25	3	1
Omicron (B.1.1.529)	Anti-RBD	0.91	80.82-100%	1.198	87.5	95	21	19	1	3
	Anti-SmT1	0.925	85.22-99.78%	1.475	83.33	85	20	17	3	4

Abbreviations: AUC: area under the curve; CI: confidence intervals; FN: false negative; FP: false positive; NA: not applicable; RBD: receptor binding domain; Anti-SmT1: Anti-spike; TN: true negative; TP: true positive.

**Supplemental Table 4. Conversion of relative ratios to international units (BAU/mL) for plasma or serum.**

<b>Nucleocapsid</b>						
Dilution fold (d)		160		640		Note
Volume (ul sample/well)		0.0625		0.015625		
Relative Ratio (RR)	log <sub>2</sub> (RR)	log <sub>2</sub> (BAU/mL)	BAU/ml	log <sub>2</sub> (BAU/mL)	BAU/ml	
2	1.0	8.38	333.98	10.38	1,335.94	Upper limit of linear range
1	0.0	6.98	126.34	8.98	505.34	
0.5	-1.0	5.58	47.79	7.58	191.15	
0.396	-1.3	5.11	34.46	7.11	137.83	Positivity threshold
0.25	-2.0	4.18	18.08	6.18	72.31	
0.125	-3.0	2.77	6.84	4.77	27.35	
0.0625	-4.0	1.37	2.59	3.37	10.35	Lower limit of linear range
Formula: $\log_2(\text{BAU mL}^{-1} \text{ @ sample dilution fold } d) = (\log_2(\text{RR}) - 0.243) / 0.713 + \log_2(d)$						
<b>RBD</b>						
Dilution fold (d)		160		640		Note
Volume (ul sample/well)		0.0625		0.015625		
Relative Ratio (RR)	log <sub>2</sub> (RR)	log <sub>2</sub> (BAU/mL)	BAU/ml	log <sub>2</sub> (BAU/mL)	BAU/ml	
1	0.0	8.12	278.37	10.12	1,113.50	Upper limit of linear range
0.5	-1.0	6.82	112.63	8.82	450.51	
0.25	-2.0	5.51	45.57	7.51	182.27	
0.186	-2.4	4.95	30.97	6.95	123.89	Positivity threshold
0.125	-3.0	4.20	18.44	6.20	73.74	
0.0625	-4.0	2.90	7.46	4.90	29.84	
0.03125	-5.0	1.59	3.02	3.59	12.07	Lower limit of linear range
Formula: $\log_2(\text{BAU mL}^{-1} \text{ @ sample dilution fold } d) = (\log_2(\text{RR}) + 0.612) / 0.766 + \log_2(d)$						
<b>Spike</b>						
Dilution fold (d)		160		640		Note
Volume (ul sample/well)		0.0625		0.015625		
Relative Ratio (RR)	log <sub>2</sub> (RR)	log <sub>2</sub> (BAU/mL)	BAU/ml	log <sub>2</sub> (BAU/mL)	BAU/ml	
1	0.0	2.55	5.86	6.55	93.80	Upper limit of linear range
0.5	-1.0	1.28	2.42	5.28	38.75	
0.25	-2.0	0.00	1.00	4.00	16.01	
0.19	-2.4	-0.50	0.70	3.50	11.28	Positivity threshold
0.125	-3.0	-1.28	0.41	2.72	6.61	
0.0625	-4.0	-2.55	0.17	1.45	2.73	
0.03125	-5.0	-3.83	0.07	0.17	1.13	Lower limit of linear range
Formula: $\log_2(\text{BAU mL}^{-1} \text{ @ sample dilution fold } d) = (\log_2(\text{RR}) - 0.604) / 0.784 + \log_2(d)$						

Abbreviations: BAU: Binding antibody unit. RBD: Receptor binding domain.